Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charlie W Lees

Showing results (31-40 of 96) with videos related to

Pageof 10
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 18, 2020
Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn's DiseaseNikolas Plevris, James Fulforth, Mathew Lyons, et al.
Journal of Crohn'S & Colitis|August 20, 2014
Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50 yearsNicholas A Kennedy, Annalie Clark, Andrew Walkden, et al.
Journal of Crohn'S & Colitis|August 24, 2023
Validation of the ACE [Albumin, CRP, and Endoscopy] Index in Acute Colitis: Analysis of the CONSTRUCT datasetRebecca K Grant, Gareth-Rhys Jones, Nikolas Plevris, et al.
Therapeutic Advances in Gastroenterology|August 1, 2024
Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitisBeatriz Gros, Hannah Ross, Maureen Nwabueze, et al.
Inflammatory Bowel Diseases|February 21, 2018
The Impact of NOD2 Variants on Fecal Microbiota in Crohn's Disease and Controls Without Gastrointestinal DiseaseNicholas A Kennedy, Christopher A Lamb, Susan H Berry, et al.
Inflammatory Bowel Diseases|June 20, 2024
The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical ProgramVipul Jairath, David T Rubin, Bram Verstockt, et al.
Plos One|March 4, 2014
The impact of different DNA extraction kits and laboratories upon the assessment of human gut microbiota composition by 16S rRNA gene sequencingNicholas A Kennedy, Alan W Walker, Susan H Berry, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 31, 2025
Large-scale clustering of longitudinal fecal calprotectin and C-reactive protein profiles in inflammatory bowel diseaseNathan Constantine-Cooke, Marie Vibeke Vestergaard, Nikolas Plevris, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 25, 2022
Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's diseaseLauranne A A P Derikx, Nikolas Plevris, Shanna Su, et al.
Inflammatory Bowel Diseases|June 24, 2020
The ACE (Albumin, CRP and Endoscopy) Index in Acute Colitis: A Simple Clinical Index on Admission that Predicts Outcome in Patients With Acute Ulcerative ColitisRebecca K Grant, Gareth-Rhys Jones, Nikolas Plevris, et al.
Pageof 10

Showing results (31-40 of 96) with videos related to

Sort By:
Pageof 10
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 18, 2020
Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn's DiseaseNikolas Plevris, James Fulforth, Mathew Lyons, et al.
Journal of Crohn'S & Colitis|August 20, 2014
Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50 yearsNicholas A Kennedy, Annalie Clark, Andrew Walkden, et al.
Journal of Crohn'S & Colitis|August 24, 2023
Validation of the ACE [Albumin, CRP, and Endoscopy] Index in Acute Colitis: Analysis of the CONSTRUCT datasetRebecca K Grant, Gareth-Rhys Jones, Nikolas Plevris, et al.
Therapeutic Advances in Gastroenterology|August 1, 2024
Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitisBeatriz Gros, Hannah Ross, Maureen Nwabueze, et al.
Inflammatory Bowel Diseases|February 21, 2018
The Impact of NOD2 Variants on Fecal Microbiota in Crohn's Disease and Controls Without Gastrointestinal DiseaseNicholas A Kennedy, Christopher A Lamb, Susan H Berry, et al.
Inflammatory Bowel Diseases|June 20, 2024
The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical ProgramVipul Jairath, David T Rubin, Bram Verstockt, et al.
Plos One|March 4, 2014
The impact of different DNA extraction kits and laboratories upon the assessment of human gut microbiota composition by 16S rRNA gene sequencingNicholas A Kennedy, Alan W Walker, Susan H Berry, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 31, 2025
Large-scale clustering of longitudinal fecal calprotectin and C-reactive protein profiles in inflammatory bowel diseaseNathan Constantine-Cooke, Marie Vibeke Vestergaard, Nikolas Plevris, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 25, 2022
Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's diseaseLauranne A A P Derikx, Nikolas Plevris, Shanna Su, et al.
Inflammatory Bowel Diseases|June 24, 2020
The ACE (Albumin, CRP and Endoscopy) Index in Acute Colitis: A Simple Clinical Index on Admission that Predicts Outcome in Patients With Acute Ulcerative ColitisRebecca K Grant, Gareth-Rhys Jones, Nikolas Plevris, et al.
Pageof 10